New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

KALA BIO, Inc.

Contributing Author

Recent Articles by KALA BIO, Inc.

Mar-30	KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live KALA GlobeNewswire
Mar-18	Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate KALA GlobeNewswire
Mar-11	Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates KALA +24.16% GlobeNewswire
Mar-04	KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform "Researgency" KALA GlobeNewswire
Jan-05	KALA BIO Settles Approximately $10.6 million of Debt KALA +6.90% KALA GlobeNewswire
Dec-05	KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules KALA -6.86% KALA -6.64% GlobeNewswire
Dec-04	KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules KALA GlobeNewswire
Dec-01	KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar KALA +37.67% GlobeNewswire
Sep-29	KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint KALA -89.27% GlobeNewswire
Sep-03	KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference KALA +23.13% GlobeNewswire
Sep-02	KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director KALA +8.65% GlobeNewswire
Aug-08	KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update KALA GlobeNewswire
Aug-06	KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference KALA GlobeNewswire
Jul-09	KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) KALA +22.09% GlobeNewswire
Jul-07	KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) KALA GlobeNewswire
May-29	KALA BIO to Present at Jefferies Global Healthcare Conference KALA GlobeNewswire
May-14	KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update KALA -6.03% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)